About Quro Pipeline Organization News ContactHome Site Map INNOVATION IN INFECTIOUS DISEASES TREATMENT.

Slides:

Advertisements

Similar presentations

2nd Panel, Best Practices: “ IPR in Successful University-Industry Collaborations” Dr. Tamar Raz, CEO Hadasit, the Technology Transfer Company of Hadassah.

Advertisements

BUY Recommendation: Gilead Sciences (GILD). Company Overview Gilead Sciences, Inc. is a research-based biopharmaceutical company found in 1987 that discovers,

Prize4Life: Inducement Prizes for ALS (Lou Gehrig’s Disease) Nicole Szlezak Member, Board of Directors Prize4Life.

Bio-technology - The Readiness of Hong Kong Opening Speech by Dr. K. S. Lo Chairman, GEM Listing Committee, Hong Kong Exchanges and Clearing Ltd. 21 October.

Biotechnology Incubators in Israel. The Israeli Biotechnology Market 160 companies (30% in therapeutics) 4000 employees Market valuation: $3.5 billion.

1 Institute of Epidemiology and Infectious Diseases Research Activities The L.V. Gromashevsky Institute of Epidemiology and Infectious Diseases Svetlana.

Bindley Bioscience Center Vision: Nurture interactive communication and interdisciplinary discovery with flexible laboratory project spaces and an open.

McLean Promotion to Associate Professor at Harvard Medical School Maureen T. Connelly, MD, MPH McLean Hospital February 3, 2010.

BIOTECHNOLOGY COMPANIES AND INFECTIOUS DISEASE Devon Sherwood, Michael Deganich, Tyler Fulton.

SUCCESS FACTORS IN THE PHARMACEUTICAL MARKETPLACE

HC70A Winter 2006 Genetic Engineering in Medicine, Agriculture, and Law Professor Bob Goldberg Class Announcements 2/2/06.

European Technology Platform – Innovative Medicines for Europe 1 st Workshop on Education and Training, 24 & 25 February 2005 Educational gaps in the R&D.

DEDICATED ONCOLOGY CLUSTER Oslo Cancer Cluster is a research and oncology cluster within the field of oncology. We are dedicated to accelerating the development.

PANEL Presentation 4 October 2004 Dr Mark Heffernan CEO.

CyteVice Alvin Dabhi Aditya Sai 5/1/2013 “Discover the discovery”

Bio-Tech Israel 2005 Conference & Exhibition May 24 – 26, 2005 David Intercontinental Hotel, Tel Aviv, Israel.

1 ECPM Research Thomas D. Szucs & Fritz R Bühler.

BioSciencs Foro November 8th, New York Joaquin Guinea Chairman of BIOMADRID (

The Nobel Prize in Physiology or Medicine 1994 "for their discovery of G-proteins and the role of these proteins in signal transduction in cells"

INTEGRATED PROJECT MUCOSAL VACCINES FOR POVERTY-RELATED DISEASES MUVAPRED MUVAPRED Project Summary Human Immunodeficiency Virus and Mycobacterium tuberculosis.

Partnering with Federal Labs: A Panel Discussion FLC Mid-Atlantic Region Annual Meeting October 24, 2007.

Department of Urology and Urologic Oncology Innovative & Modern Medicine in Urology and Urologic Oncology Hannover Medical School is one of the highest-capacity.

Early Stage Funding for Biotechnology Ventures-Jan 2003 Sarath Naru The Biotechnology Venture Fund Ventureast Tenet Fund APIDC – Venture Capital Fund.

What ? Who ? Why ?. What is WebmedCentral? Webmed Limited is a unique biomedical publishing company with a twin approach to scientific publishing.

Technology Transfer Center of the University of Lodz High-Tech Accelerator - Innovation Center Foundation of the University of Lodz Bridging science and.

Life Science Venture Capital 11th Annual NIH SBIR/STTR Conference July 1, 2009 Randy H. Weiss, Ph.D. Partner, Triathlon Medical Ventures.

Breakthrough Technology for a Brighter Future. Oramed Pharmaceuticals OTC Bulletin Board: ORMP Company with oral drug delivery platform Based on over.

The 2nd Annual General Meeting of Shareholders March 21, 2003 Proposed Agenda - translation – This material is a English translated version of the original.

1 EU-funded health research activities against TB: FP6 actions and perspectives toward FP7 DG Research - European Commission 22 MARCH 2007.

R&D IN HUNGARY National Research and Technological Innovation Fund Independent central government office responsible for R&D Expected new budget: approx.

State University of New York at Stony Brook Clinton Rubin, Ph.D. Professor & Chair Department of Biomedical Engineering Forum on Innovation and Entrepreneurship.

April 2003Takuji Hara, Kobe University 1 Roles of Technology Licensing Organizations (TLOs) in the Commercialization of Life Sciences ～ Japan ’ s Situation.

Ownership of genetic materials, and benefits sharing (ATRIP, 4 August Session 3) Robert Kneller, J.D., M.D. Professor, Department of Intellectual Property.

Life Sciences Trend Analysis 2013 UNITED KINDGOM.

Social Media Going Viral Against HIV/STI s Marketing Campaign New York State Department of Health AIDs Institute.

Country Report on Asian ALARA Networking Meeting LIU Senlin China Institute of Atomic Energy P.O. Box 275(1), Beijing Fax: Tel:

Consortium for Interdisciplinary Studies on Science for Aging.

Virtual Biotech Model for Parkinson’s UK Arthur Roach, Director of Research.

Jeff Behrens Head of Business Operations Biogen Idec Innovation Incubator 10/2/2007 Getting Initial Money to go from Nothing to Something.

Young Woo Medical Company Profile Young Woo Medical CEO : Na Young Lee 16, Je4sandan 1-ro, Miyang-myeon, Anseong-si, Gyeonggi-do, Republic of Korea Tel.

R&I policy in Ukraine Ministry of Education and Science of Ukraine Dmytro Cheberkus Director of the Department of Science and Technology Development, PhD.

1 Catapult Corporation: Venture Philanthropy Creating Managed Investment Capital for Extraordinary Companies Created at the University of Arizona David.

The next generation platform for the isolation of fully human monoclonal antibodies Corporate Overview Co.

The U.K. Life-Sciences Trend Analysis About Us The following statistical information has been obtained from Biotechgate. Biotechgate is a global,

R&I policy in Ukraine Ministry of Education and Science of Ukraine Dmytro Cheberkus Director of the Department of Science and Technology Development, PhD.

Pioneering patient-centred, side-effect free cancer treatments.

May 18 th, 2007 Biotech Symposium - From Genome to Therapeutics -

1 Promotion in Management and Research Tracks in Industry Magdalena Alonso-Galicia, PhD Cardiovascular Diseases Department Merck Research Laboratories.

The most focused funder of neuroendocrine cancer research launches $2 million immunotherapy initiative (1888 PressRelease) After a year of reviewing the.

Nucorion Pharmaceuticals, Inc. Overview Ligand Non-Confidential Nucorion Pharmaceuticals, Inc.  Newly formed US-based biotech company, initially.

Success Stories of Globalization in Korean Pharma

The University at Albany Health Sciences Campus

Dr. Siegfried Bialojan Background Skills Professional experience

KORN/FERRY INTERNATIONAL

Peter K. Thies, Ph.D. Senior Partner Leadership and Talent Consulting

Co-founder of Nanotech Energy, Inc, LonglifeRx, Inc, SuperMetalix, Inc and Novonco Theraputics, Inc.Nanotech Energy, Inc Jack Kavanaugh.

Jack Kavanaugh MD, MBA Chairman, Acting CEO. Founder of numerous medical and biotech companies Jack Kavanaugh is globally recognized doctor and businessman.

Jack Kavanaugh An ophthalmologist, dentist, and entrepreneur Chairman & Acting CEO of Medical and Science Technology Companies.

Jack Kavanaugh Chairman of the board, CEO and Co-founder of several technologies driven Companies.

Jack Kavanaugh Noted doctor and business leader in the biotechnology and medical world.

Private sector involvement IPM-Tibotec case study

The Art of Capturing Pluripotency: Creating the Right Culture

Investment Opportunity and

Tamar Raz, PHD.

Dr. Sanjay Patel | Mayflower Womens Hospital | Elawoman

Division of AIDS Office of the Director Workforce Operations,

Biotechnology Training & Researching in University of Natural Science

Presentation transcript:

About Quro Pipeline Organization News ContactHome Site Map INNOVATION IN INFECTIOUS DISEASES TREATMENT

About Quro Pipeline Organization News ContactHome Site Map Quro Science Inc. Quro is a spin-off biotechnology company from Institut Pasteur Korea (IP-K) committed to develop novel therapeutics against infectious diseases. Quro’s main focus is on human immunodeficiency virus (HIV), hepatitis C virus (HCV) and tuberculosis (TB) infection. Quro has exclusive rights to develop and commercialize drug candidates discovered with IP-K’s proprietary state-of-the-art technologies including the PhenomicScreen TM and PhenomicID TM platforms. Quro has in-house expertise in preclinical and clinical development management and operates as a virtual company using contract research organizations (CROs) for execution of the development works. Quro intends to license out the products in the course of the clinical development to larger partners for further development.

About Quro Pipeline Organization News ContactHome Site Map Quro’s Operations Model

About Quro Pipeline Organization News ContactHome Site Map

About Quro Pipeline Organization News ContactHome Site Map

About Quro Pipeline Organization News ContactHome Site Map Organizational Chart

About Quro Pipeline Organization News ContactHome Site Map Management Team Dr. Ulf Nehrbass, CEO Dr. Nehrbass graduated in Biochemistry from Cambridge University, UK, and obtained his Ph.D. at the EMBL in Heidelberg, Germany in After a postdoctoral position in the Howard Hughes Medical Institute at the Rockefeller University, New York, he joined the Institut Pasteur in Paris, in 1998 where he was Head of the Nuclear Cell Biology unit and CNRS Research Director. After a number of research awards he was elected member of EMBO in He has been CEO of IP-Korea since its inception in 2004.

About Quro Pipeline Organization News ContactHome Site Map Board of Directors Dr. Ulf Nehrbass Head of the Nuclear Cell Biology unit, Institut Pasteur in Paris CNRS Research Director CEO of Institut Pasteur Korea Dr. Yung Bog Chae Chairman of Institut Pasteur Korea Board of Directors Chairman of Gyeonggi Bio-Center Former Minister, Ministry of Science and Technology, Republic of Korea Mr. Seok Won Yoon General Manager, Hanwha Venture Capital Corp. Director, Green & Biotech, Inc. General Manager, Basic Venture Capital, Co., Ltd

About Quro Pipeline Organization News ContactHome Site Map Board of Directors Dr. Yongmo Lee Director, Center for International Cooperation, National Research Foundation Associate Professor, Dr. Myung Whan Park Director of Gyeonggi Bio-Center Dr. Jae Whan Park Professor, Department of Business and Management School Of Social Science, Chung-Ang University External Auditor

About Quro Pipeline Organization News ContactHome Site Map Bulletin board here

About Quro Pipeline Organization News ContactHome Site Map Quro Science Inc. Sampyeong-dong 696 Bundang-gu Seongnam-si Gyeonggi-do, Korea Tel: Fax: Quro Science Inc. Sampyeong-dong 696 Bundang-gu Seongnam-si Gyeonggi-do, Korea Tel: Fax: